Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up—A CLARICOR Trial Sub-Study

Erik Nilsson 1,2,* , Jens Kastrup 3, Ahmad Sajadieh 4, Gorm Boje Jensen 5, Erik Kjøller 6,11, Hans Jørn Kolmos 7, Jonas Wuopio 8, Christoph Nowak 9, Anders Larsson 10, Janus Christian Jakobsen 11,12, Per Winkel 11, Christian Gluud 11, Kasper K Iversen 6, Johan Ärnlöv 9,13 and Axel C. Carlsson 9

1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden
2 School of Medical Sciences, Örebro University, 70182 Örebro, Sweden
3 Department of Cardiology, Rigshospitalet University of Copenhagen, 2100 Copenhagen, Denmark; jens.kastrup@regionh.dk
4 Department of Cardiology, Copenhagen University Hospital of Bispebjerg and Frederiksberg, 2000 Frederiksberg, Denmark; ahmad.sajadieh@regionh.dk
5 Department of Cardiology, Hvidovre Hospital University of Copenhagen, 2650 Hvidovre, Denmark; gorm.boje.jensen.01@regionh.dk
6 Department of Cardiology S, Herlev Hospital University of Copenhagen, 2730 Herlev, Denmark; kjoller@dadlnet.dk (E.K.); kasper.karmark.iversen@regionh.dk (K.K.I.)
7 Department of Clinical Microbiology, Odense University Hospital, 5000 Odense, Denmark; h.j.kolmos@dadlnet.dk
8 Department of Medicine, Mora County Hospital, 79251 Mora, Sweden; jonas.wuopio@tldalarna.se
9 Division for Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 14183 Huddinge, Sweden; christoph.nowak@ki.se (C.N.); axelcefam@hotmail.com (A.C.C.)
10 Department of Medical Sciences, Uppsala University, 75185 Uppsala, Sweden; anders.larsson@akademiska.se
11 Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark; janus.jakobsen@ctu.dk (J.C.J.); per.winkel@ctu.dk (P.W.); christian.gluud@ctu.dk (C.G.)
12 Department of Cardiology, Holbæk Hospital, 4300 Holbæk, Denmark
13 School of Health and Social Studies, Dalarna University, 79131 Falun, Sweden; johan.arnlov@ki.se

* Correspondence: erik.alfred.nilsson@gmail.com

Received: 5 December 2019; Accepted: 15 January 2020; Published: 20 January 2020

Abstract: Elevated pregnancy-associated plasma protein A (PAPP-A) is associated with mortality in acute coronary syndromes. Few studies have assessed PAPP-A in stable coronary artery disease (CAD) and results are conflicting. We assessed the 10-year prognostic relevance of PAPP-A levels in stable CAD. The CLARICOR trial was a randomized controlled clinical trial including outpatients with stable CAD, randomized to clarithromycin versus placebo. The placebo group constituted our discovery cohort (n = 1,996) and the clarithromycin group the replication cohort (n = 1,975). The composite primary outcome was first occurrence of cardiovascular event or death. In the discovery cohort, incidence rates (IR) for the composite outcome were higher in those with elevated PAPP-A (IR 12.72, 95% Confidence Interval (CI) 11.0–14.7 events/100 years) compared to lower PAPP-A (IR 8.78, 8.25–9.34), with comparable results in the replication cohort. Elevated PAPP-A was associated with increased risk of the composite outcome in both cohorts (discovery Hazard Ratio (HR) 1.45, 95% CI 1.24–1.70; replication HR 1.29, 95% CI 1.10–1.52). In models adjusted for established risk factors, these trends were attenuated. Elevated PAPP-A was associated with higher all-cause mortality in
both cohorts. We conclude that elevated PAPP-A levels are associated with increased long-term mortality in stable CAD, but do not improve long-term prediction of death or cardiovascular events when added to established predictors.

**Keywords:** pregnancy-associated plasma protein-A; coronary artery disease; cohort studies; biomarkers

---

1. Introduction

Pregnancy-associated plasma protein-A (PAPP-A) is a cell membrane-bound metalloproteinase which regulates local availability of insulin-like growth factor 1 (IGF-1) [1]. It has been evaluated as a prognostic biomarker in acute coronary syndromes [2–11], where elevated levels are associated with increased risk of death. However, this association may be confounded by heparin treatment causing elevated PAPP-A levels in vivo through release of PAPP-A attached to cell membranes [12]. Further, PAPP-A levels predict cardiovascular events in troponin-negative patients with suspected acute coronary syndrome [3] and higher levels of circulating PAPP-A are associated with more extensive coronary artery disease [13] as well as with plaque inflammation and echogenicity [14]. In chronic stable angina pectoris PAPP-A has been less extensively studied and is associated with outcomes in some studies [15–18] but not all [19]. Studies with long-term follow-up are scarce.

PAPP-A regulates downstream growth hormone effects in the paracellular environment by cleaving insulin-like growth factor binding protein 4 (IGFBP4) bound to insulin-like growth factor 1 (IGF-1), thereby making IGF-1 available to its receptor. Since PAPP-A is normally bound to the cell membrane and not abundantly expressed, increased plasma levels in the absence of heparin treatment may represent up-regulation due to inflammation or tissue damage, in combination with escape into the circulation [20–22].

The present study is part of the larger PREdictors for MAjor Cardiovascular outcomes in stable ischemic heart disease (PREMAC) study, which aimed to identify biochemical predictors of cardiovascular events and all-cause mortality in persons with stable coronary artery disease (CAD) utilizing data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial [23]. In the CLARICOR Trial, patients were randomized to clarithromycin or placebo and the main outcomes consisted of myocardial infarction (AMI), unstable angina pectoris (UAP), cardiovascular mortality, and all-cause mortality. In a previous report on the same cohort, elevated PAPP-A, defined as values ≥ 4 µ/mL, was found to predict risk of death and myocardial infarction during medium term (median 2.8 years) follow up [17]. The aim of the present study was to assess the predictive power of elevated PAPP-A levels for the 10-year outcomes in stable CAD.

2. Experimental Section

The PREMAC study focused on the presence of predictors of cardiovascular events and all-cause mortality in persons with stable CAD and included a detailed statistical analysis plan [23]. Biomarker assessment was performed using stored biobank samples from the CLARICOR trial [24] and outcome data was retrieved from public registers. The CLARICOR trial was approved by local ethics committees and regulatory authorities (Regional Ethics Committee HB 2009/015 and KF 01-076/99; the Danish Data Protection Agency 1999–1200–174 and 2012–41–0757; and the Danish Medicines Agency 2612–975).

2.1. Patient Selection

The CLARICOR trial was a randomized, placebo-controlled trial with blinded outcome assessment including outpatients with stable CAD. All patients discharged from wards or outpatient clinics in the Copenhagen area in Denmark with a diagnosis of acute myocardial infarction or unstable angina
pectoris during the years 1993–1999 who were alive and aged 18–85 years old in 1999 (n = 13,702) were invited to a screening interview at one of five cardiology centers. Of the 6116 (44.6%) patients accepting the invitation, 1567 (25.6%) were excluded, 177 (2.9%) chose not to participate, and the remaining 4372 (71.5%) were randomized to oral clarithromycin 500 mg once daily for 2 weeks (n = 2,172) vs. placebo (n = 2,200) during the winter 1999–2000. Exclusion criteria of the CLARICOR trial were: AMI or UAP within the previous 3 months, percutaneous transluminal coronary angioplasty and coronary bypass surgery within the previous 6 months, impaired renal or hepatic function, congestive heart failure (New York Heart Association (NYHA) IV classification of heart failure), active malignancy, incapacity to manage own affairs, breast feeding, and possible pregnancy. In the CLARICOR trial, clarithromycin was found to increase both the risk of cardiovascular and all-cause mortality [24–27].

The patients randomized to placebo in the CLARICOR study were included as the discovery cohort in the present study, while those randomized to clarithromycin formed the replication cohort. We excluded participants with missing data in any of the variables, leaving n = 1,996 (92%) in the discovery cohort, and n = 1,975 (90%) in the replication cohort.

2.2. Baseline Data

During enrollment interviews, smoking status, current medication, and known hypertension or diabetes were noted. Information concerning sex, age, and history of myocardial infarction or unstable angina pectoris were extracted from local hospital files. Blood samples were collected at each of the study sites immediately before randomization, using blood collection tubes without additives. Serum was prepared according to normal hospital routine with approximately coagulation for 30 min and centrifugation at 1500 g for 10 min. Serum was frozen on the day of collection at −20 °C and at −80 °C after transportation to the central laboratory facility. Storage problems were the only noteworthy cause of missing data. Estimated glomerular filtration rate (eGFR) was calculated using the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [28]. Smoking status was categorized as never, former, or current smoker. No physical investigations were made at randomization interview; nor were any longitudinal predictor information collected during follow-up.

2.3. Pregnancy-Associated Plasma Protein A Levels

The PAPP-A levels measured in a previous study were used in the present study [17]. The enzyme-linked immunosorbent assay used for quantification of PAPP-A has been described in detail previously [17,29]. The detection limit was 4 mIU/L. The intra-assay coefficient of variation was 2.0% at 71.7 mIU/L and 5.7% at 10.4 mIU/L, with corresponding inter-assay coefficients of variation of 6.4% and 8.7%, respectively. Elevated serum PAPP-A was defined as values at or above 4 mIU/L, based on levels in healthy blood donors [29]. Note that although the CLARICOR trial data did not include information on heparin use, study participants were outpatients with stable CAD and heparin is not used in this setting.

2.4. Outcomes

Follow-up was until 31 December 2009 where the official permissions expired. Outcome data was procured from national patient registries. These are mandatory for inpatient care and all events diagnosed and coded during hospital admission are therefore detected, resulting in virtually no loss to follow-up. Vital status was retrieved from the Danish Central Civil Register, cause of death from the National Register of Causes of Death, and hospital admissions from the Danish National Patient Register (NPR), which covers all hospital admissions. These registries have almost complete coverage [30]. By trial protocol, events during the first 2.6 years of follow-up were adjudicated by a blinded committee, previously described in detail [23,24]. For the 10-year studies, registry outcomes were used after verifying that the results were consistent with those based on adjudication data [30,31].
The Danish 10-digit central person registration (CPR) number is used at all contacts with the health care system. At discharge from hospital, at least one action diagnosis (A diagnosis) specifying the main reason for the admission is noted in the NPR. These A diagnoses, and in case of death the ‘underlying cause of death’ code (in the official terminology of the National Register of Causes of Death), was used for classifying outcomes according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) coding system as follows: AMI (I21.0–23.9), UAP (I20.0 and I24.8–24.9), cerebrovascular disease (CeVD) (I60.0–64.9 and G45.0–46.8), cardiovascular death (I00.0–99.9 unless already covered), and death due to non-cardiovascular disease (A00.0–T98.3 unless already covered). A composite outcome was defined as AMI, UAP, CeVD, or death due to any cause. Follow-up time was censored at occurrence of an outcome, death, or end of follow-up (31st December 2009 giving a median possible survival time of 10 years ± 3 months after randomization).

2.5. Statistical Analysis

Incidence rates (IR) were calculated using only the first occurrence of an event and the time to event or censoring at end of study was used in the denominator. We used Cox proportional hazards model for the statistical analysis. Multivariable models were adjusted according to the pre-specified analysis plan, for clinical predictors (sex, age at randomization, smoking history, history of myocardial infarction, hypertension, and diabetes), medical treatment (acetylsalicylic acid, beta-blocker, calcium-antagonist, angiotensin-converting enzyme (ACE)-inhibitor, long lasting nitrate, diuretic, digoxin, statin, and anti-arrhythmic drugs), and standard biochemical predictors (log-transformed high-sensitivity-reactive protein (CRP), glomerular filtration rate (GFR) estimated by creatinine, triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein A1, and apolipoprotein B). Standard predictors adjusted for in multivariable models are listed in Appendix A. Triglycerides and total cholesterol were log transformed.

As the proportional hazard’s assumption was violated for age at entry for all-cause death and the composite outcome (Bonferroni adjusted \( p < 0.0044 \) for all-cause mortality; and \( p < 0.00056 \) for the composite outcome), we excluded age from all models for these two outcomes. In order to provide additional insights into the potential influence of age on these associations, we conducted multivariable logistic regression models (including age as a co-variate since the proportional hazard assumption is not a requisite for these analyses).

3. Results

Baseline characteristics of the discovery and replication cohorts are presented in Table 1. They showed no major differences between the cohorts. The proportion of participants with elevated PAPP-A levels was 13% (\( n = 263 \)) in the discovery cohort and 12% (\( n = 244 \)) in the replication cohort.

Table 2 displays outcomes by PAPP-A level. In the discovery cohort, the composite outcome was more common among those who elevated PAPP-A, compared to those with low PAPP-A levels (72% compared to 59%), with a corresponding difference in incidence rates (\( p < 0.0001 \)). The same pattern was seen in the replication cohort.
Table 1. Baseline characteristics of the two study cohorts.

| Variable                        | Discovery Cohort | Replication Cohort |
|---------------------------------|------------------|--------------------|
| Number of participants          | 1996             | 1975               |
| PAPP-A ≥ 4 mIU/L                | 263 (13)         | 244 (12)           |
| Female                          | 623 (31)         | 602 (30)           |
| Age at entry, years             | 65 ± 10          | 65 ± 10            |
| CRP, mg/L                       | 5.25 ± 7.7       | 5.76 ± 9.3         |
| Apolipoprotein A1, mg/dL        | 1.70 ± 0.34      | 1.70 ± 0.36        |
| Apolipoprotein, mg/dL           | 1.21 ± 0.32      | 1.21 ± 0.33        |
| eGFR, mL/min                    | 76.3 ± 20        | 76.5 ± 19          |
| Diabetes mellitus               | 299 (15)         | 301 (15)           |
| Hypertension                    | 805 (40)         | 790 (40)           |
| Never smoked                    | 394 (20)         | 339 (17)           |
| Former smoker                   | 925 (46)         | 903 (46)           |
| Current smoker                  | 677 (34)         | 735 (37)           |
| History of myocardial infarction| 635 (32)         | 640 (32)           |
| Statin treatment                | 822 (41)         | 812 (41)           |
| Aspirin treatment               | 1763 (88)        | 1733 (88)          |
| Beta blocker treatment          | 619 (31)         | 589 (30)           |
| Calcium antagonist treatment    | 702 (35)         | 680 (34)           |
| ACE inhibitor treatment         | 522 (26)         | 552 (28)           |
| Long-acting nitrate treatment   | 412 (21)         | 411 (21)           |
| Diuretics treatment             | 690 (35)         | 698 (35)           |
| Digoxin treatment               | 115 (6)          | 138 (7)            |
| Antiarrhythmic treatment        | 42 (2)           | 46 (2)             |

Baseline characteristics in the discovery (placebo) and replication (clarithromycin) cohorts, presented as mean ± standard deviation for continuous variables and n (%) for categorical variables. Abbreviations: PAPP-A: pregnancy-associated plasma protein A; CRP: high sensitivity C-reactive protein; eGFR: estimated glomerular filtration rate; ACE: angiotensin converting enzyme.

Table 2. Incidence rates of the composite outcome by PAPP-A level.

| PAPP-A Category | Variable                      | Discovery Cohort | Replication Cohort |
|-----------------|-------------------------------|------------------|--------------------|
|                 | N                             | 263              | 244                |
| PAPP-A ≥ 4 mIU/L| Outcomes, N (%)               | 189 (72)         | 168 (69)           |
|                 | IR per 100 years              | 12.72            | 12.04              |
|                 | 95% CI                        | 11.0–14.7        | 10.35–14.01        |
|                 | N                             | 1733             | 1731               |
| PAPP-A < 4 mIU/L| Outcomes, N (%)               | 1015 (59)        | 1052 (61)          |
|                 | IR per 100 years              | 8.78             | 9.38               |
|                 | 95% CI                        | 8.25–9.34        | 8.83–9.96          |

The composite outcome was defined as acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, or death due to any cause. Outcomes (with % of participants at risk) is the number of persons experiencing the composite outcome during 10-years follow-up. Incidence rates (IR) were calculated using only the first occurrence of the outcome during follow-up. Abbreviations: PAPP-A: pregnancy-associated plasma protein A; CI, Confidence Interval.

In the survival analysis (Table 3), Cox proportional hazards models adjusted for sex (model A) showed that PAPP-A ≥ 4 µ/mL was associated with an increased risk of the composite outcome in the discovery cohort and, less markedly, in the replication cohort; with adjustment for a large number of other risk factors (model B, see Table 3), comprising comorbidities and biochemical markers, these risk trends were attenuated in the discovery cohort and disappeared in the replication cohort.
Table 3. Risk of composite outcome associated with the binary covariate elevated PAPP-A.

| Variable | Discovery Cohort | Replication Cohort |
|----------|------------------|--------------------|
|          | Model A          | Model B            | Model A         | Model B         |
| Hazard ratio | 1.45 (1.24–1.70) | 1.28 (1.08–1.50)  | 1.06 (0.89–1.25) |
| 95% CI   | < 0.001          | < 0.001            | 0.003           | 0.51            |
| p-value  |                  |                    |                 |                 |

Cox proportional hazards models are applied to the composite outcome defined as acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, or death due to any cause. Model A was adjusted for sex. Model B was adjusted for established risk factors and co-morbidities, standard biochemical predictors, and treatments as listed in Appendix A. All models in this table are shown without adjustments for age at entry. Abbreviations: PAPP-A, pregnancy-associated plasma protein A.

Comparable results, with elevated PAPP-A being associated with increased risk of the composite outcome in the discovery cohort, but not in the replication cohort, were found in adjusted logistic regression models (Table S1) where age was also included in the multivariable model. We found no interaction between sex and PAPP-A on mortality \( (p = 0.22) \) or on the composite outcome \( (p = 0.17) \).

The association between PAPP-A \( \geq 4 \) mIU/L and other outcomes is shown in Table S2. Elevated PAPP-A was associated with higher all-cause mortality in the discovery cohort, an association that remained in the fully adjusted analysis as well as in a logistic regression that included age as a predictor variable (Table S1). These findings were reproduced in the replication cohort.

Interestingly, these secondary analyses suggest that PAPP-A elevation is at least as strong a predictor for non-cardiovascular as for cardiovascular death (Table S2).

We also evaluated the predictive utility of PAPP-A in the group of placebo-treated patients when added to a large number of standard predictors (Table S3). Adding elevated PAPP-A as a predictor produced no visible improvements (apart from a slight numerical instability).

4. Discussion

Our main finding is that PAPP-A levels \( \geq 4 \) mIU/L are associated with increased long-term risk of composite adverse outcome as well as all-cause mortality in patients with stable CAD. Although the association to all-cause mortality remained after extensive multivariable adjustment, the association to the composite outcome was not reproduced in our replication cohort when adjusted for many other risk factors. This may indicate that the placebo group and the clarithromycin treated group (the replication group) are not completely compatible in that clarithromycin was found to increase mortality \( [24–27] \). It may also indicate that the association between PAPP-A and outcomes is confounded by some of these other risk factors, for example diabetes \( [20,32] \). Over-adjustment may also be a problem in this context \( [33] \). Our choice of covariates in the various multivariate analyses was mandated by the choice made for the Cox analyses of the placebo-treated patients described in the pre-specified analysis plan.

The growth hormone (GH) axis and PAPP-A has been implicated in the progression of atherosclerosis. Locally, insulin-like growth factor 1 (IGF-1) promotes multiple mechanisms involved in plaque formation and an association between PAPP-A and atherosclerosis has been demonstrated \( [2,34] \). PAPP-A is found in atherosclerotic plaques on cell-types involved in the atherosclerotic process, including vascular smooth muscle cells, endothelial cells and macrophages \( [1] \), its expression is elevated in vulnerable plaques \( [2] \). PAPP-A activity is related to atherosclerotic lesion size in rodents \( [35,36] \) and higher levels of circulating PAPP-A are associated with more extensive coronary artery disease in humans \( [13] \).

Reduced PAPP-A activity is associated with diminished vascular cell proliferation in response to injury, reduced plaque area and less luminal occlusion in atherosclerosis \( [37] \). Conversely, increased PAPP-A activity is associated with proliferation of vascular smooth muscle cells \( [34] \). Regulation of vascular smooth muscle cell proliferation could therefore be a mechanism by which PAPP-A influences the atherosclerotic process. PAPP-A could also be linked to atherosclerosis through modulating the effects of IGF-1 on lipid-, glucose-, and protein metabolism \( [38,39] \).
However, the exact mechanism by which PAPP-A is involved (causally or as a by-product) in the promotion of atherosclerosis remains elusive, in part as a result of conflicting findings on the effects of IGF-1 action on the vasculature [40]. Notably, the relationship between serum levels of IGF-1 and PAPP-A and local IGF-1 activity is unclear and may for example be dependent on body composition, inflammation, or conditions such as diabetes mellitus or obesity [40]. Circulating levels are therefore not necessarily directly related to the hypothesized pathophysiological mechanisms by which IGF-1 and PAPP-A are implicated in development of coronary artery disease. Consequently, the association between PAPP-A and mortality described in the present study may be related to other factors than cardiovascular disease progression. Indeed, we did not find any clear association with cardiovascular outcomes and it should be noted that the IGF-1 system including PAPP-A may for example be related to development of cancer [41]. There was in our results consistently no association between elevated PAPP-A and myocardial infarction, UAP, or stroke, although there was an association to cardiovascular mortality in the minimally adjusted analysis in the replication cohort.

The association between PAPP-A levels and outcomes in stable CAD has been studied previously. In 103 stable CAD patients, with a median follow-up of 4.9 years, higher PAPP-A was associated with increased mortality as well as the composite outcome of death and acute coronary syndrome [15]. Interestingly, but potentially problematic [33], those authors adjusted their estimates for the extent of coronary atherosclerosis, which could be considered an intermediate in the hypothesized causal pathway between PAPP-A and cardiovascular events. In another cohort study, including 534 patients with stable CAD and 393 patients with acute coronary syndrome, with a median follow-up time of 5.0 years, the authors found no association to cardiovascular mortality in the subgroup stable CAD, but higher PAPP-A was associated with increased cardiovascular mortality in the overall cohort as well as in the acute coronary syndrome (ACS) subgroup [19]. Although these results were adjusted for several conventional predictors, there was no adjustment for age. In a previous study on the CLARICOR cohort participants, PAPP-A levels were studied in relation to medium-term outcomes [17]. Important differences in that study from the present study include a shorter follow-up (median 2.8 years), joining of the placebo and the treatment group in a single cohort, and differing definitions of the composite outcome. In line with our present results, the previous study found that elevated PAPP-A was associated with the composite outcome of myocardial infarction and death as well as all-cause mortality in adjusted analyses [17].

PAPP-A has also been studied in ACS, but there is limited generalizability from these studies to the context of stable CAD. In troponin-negative patients with suspected ACS, PAPP-A predicted future cardiovascular events [3], although we are uncertain if PAPP-A was sampled before administration of heparin. Others found that PAPP-A predicted cardiovascular events in ACS and it seems that PAPP-A was sampled after heparin infusion, indicating that the PAPP-A levels included PAPP-A released from the cell membrane during heparin treatment [6]. In that study, PAPP-A predicted outcomes in TnT-negative patients. Furthermore, differences in stable versus acute CAD may have support in PAPP-A physiology since chronic and transient PAPP-A expression may have differing effects on neointimal formation following vascular injury [42].

Our present study has several strengths: a large study sample, detailed characterization of the participants, longitudinal study design, 10 years follow-up, and a replication of all analyses in the clarithromycin group of the trial. As far as we know, there are no other large cohort studies on associations between PAPP-A levels in patients with stable CAD. National Danish registers are known to be of high completeness and accuracy [30], but a small number of non-fatal events can be missed when participants are hospitalized abroad. Results in our study are likely valid for patients with stable CAD as ascertained at the baseline interview and it remains to be shown if similar risks are seen for other relevant patient groups, such as patients with acute symptoms or patients during recovery from a major event.

Limitations are the unknown generalizability to other ethnic groups and to those unlikely to volunteer to participate in studies. Distortion by the active intervention with clarithromycin
cannot be excluded, although we saw similar associations as to those in the placebo cohort. As regards the replication cohort, with its previously described surplus of unfavorable cardiovascular outcomes [26,27,43], we noted that elevated PAPP-A here tended to lose its unfavorable implications. Such interaction, if present, would imply that the harmful effect of clarithromycin was more marked in those with low PAPP-A levels. However, the trend nowhere came close to statistical significance. Nor do we have any theoretical arguments in favor thereof. Another limitation is that there was no data on heparin treatment at baseline. However, as the participants in our study had no indication for heparin, it is unlikely that this lack of data would have any substantial influence on our results and conclusions. In addition, there was no data on left ventricular ejection fraction, although this may be partially or completely compensated by other covariables included in the analyses, as age, sex, hypertension, prior acute myocardial infarction, creatinine, diuretics, and digoxin are related to left ventricular ejection fraction [44].

5. Conclusions

Elevated PAPP-A levels are associated with increased long-term mortality in stable CAD, but they do not improve long-term prediction of composite outcome of death or cardiovascular events when added to established predictors.

Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/1/265/s1, Table S1: Logistic regression analyses of risk associated with elevated PAPP-A ≥ 4 mIU/L, Table S2: Risk of specific outcomes associated with elevated PAPP-A, Table S3: The role of elevated PAPP-A when used in combination with ‘standard predictors’ in the prediction of outcome status. All pertinent anonymized data will be uploaded at ZENODO (http://zenodo.org) when the individual manuscripts have been published.

Author Contributions: Conceptualization, C.G. and A.S.; methodology, C.G., J.C.J., C.N., A.L., E.N., J.Å., J.K., P.W., E.K., and J.W.; validation, C.G.; formal analysis, E.N., A.C.C., and P.W.; investigation, C.G., J.K., G.B.J., and K.K.I.; resources, C.G.; data curation, C.G. and P.W.; supervision, C.G., J.C.J. and J.Å.; project administration, C.G. and G.B.J.; funding acquisition, C.G. and K.K.I.; software, P.W.; visualization, not applicable; writing—original draft preparation, E.N., A.C.C., and J.Å.; writing—review and editing. All authors. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the Copenhagen Trial Unit, Centre for Clinical Intervention Research. The original funders of the CLARICOR trial were: The Danish Heart Foundation, grant numbers 01-1-5-21-22894, 99-2-5-103-22773, 99-1-5-87-22712, and 97-2-5-70-22537; The Copenhagen Hospital Corporation, grant date 7 October 1997; The Danish Research Council, grant numbers 9702122 and 22-00-0261; The 1991 Pharmacy Foundation, grant number HPN/ld/71-97; The Copenhagen Hospital Corporation and the Copenhagen Trial Unit. Abbott Laboratories, IDC, Queensborough, UK supplied the clarithromycin and placebo tablets.

Acknowledgments: We thank the CLARICOR trial participants. We thank the investigators and other staff involved in the first phases of the CLARICOR trial: Bodil Als-Nielsen, Morten Damgaard, Jørgen Fischer Hansen, Stig Hansen, Olav H. Helø, Per Hildebrandt, Jørgen Hilden, Inga Lind, Henrik Nielsen, Lars Petersen, Christian M. Jespersen, Maria Skoog, and Jane Lindschou.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Appendix A

Predictors Adjusted for in Multivariable Models

Predictors were pre-specified in the study protocol. Standard predictors adjusted for in multivariable models are listed below. Note that age at entry was omitted from Cox regression analyses due to violation of proportional hazard assumption when all-cause mortality and the composite outcome was analyzed.

Clinical predictors were: sex, age at entry, smoking history, history of myocardial infarction as opposed to angina only, hypertension, and diabetes.

Standard biochemical predictors were: Log-transformed high-sensitivity C-reactive protein (CRP), estimated glomerular filtration rate (eGFR) estimated by creatinine, triglycerides and lipoproteins (total
cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, apolipoprotein A1, and apolipoprotein B).

The current medical treatment was included as proxy predictors because information about post infarction heart failure and post-infarction angina pectoris are not available to us: Aspirin (Yes/No), beta-blocker (Yes/No), calcium antagonist (Yes/No), ACE inhibitor (Yes/No), long lasting nitrate (Yes/No), diuretic (Yes/No), digoxin (Yes/No), statin (Yes/No), and anti-arrhythmic drugs (Yes/No).

References
1. Steffensen, L.B.; Conover, C.A.; Oxvig, C. PAPP-A and the IGF system in atherosclerosis: what’s up, what’s down? Am. J. Physiol. Heart Circ. Physiol. 2019, 317, H1039–H1049. [CrossRef]
2. Bayes-Genis, A.; Conover, C.A.; Overgaard, M.T.; Bailey, K.R.; Christiansen, M.; Holmes, D.R.J.; Virmani, R.; Oxvig, C.; Schwartz, R.S. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N. Engl. J. Med. 2001, 345, 1022–1029. [CrossRef]
3. Lund, J.; Qin, Q.-P.; Ilva, T.; Pettersson, K.; Voipio-Pulkki, L.-M.; Porela, P.; Pulkki, K. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin i elevation. Circulation 2003, 108, 1924–1926. [CrossRef]
4. Qin, Q.-P.; Kokkala, S.; Lund, J.; Tamm, N.; Voipio-Pulkki, L.-M.; Pettersson, K. Molecular distinction of circulating pregnancy-associated plasma protein a in myocardial infarction and pregnancy. Clin. Chem. 2005, 51, 75–83. [CrossRef] [PubMed]
5. Heeschen, C.; Dimmelmeier, S.; Hamm, C.W.; Fichtlscherer, S.; Simonou, M.L.; Zeiher, A.M. Pregnancy-associated protein-a levels in patients with acute coronary syndromes: Comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J. Am. Coll. Cardiol. 2005, 45, 229–237. [CrossRef]
6. Armstrong, E.J.; Morrow, D.A.; Sabatine, M.S. Inflammatory biomarkers in acute coronary syndromes: Part IV: Matrix metalloproteinases and biomarkers of platelet activation. Circulation 2006, 113, e382–e385. [CrossRef]
7. Body, R.; Ferguson, C. Towards evidence-based emergency medicine: Best bets from the manchester royal infirmary. Pregnancy-associated plasma protein A: A novel cardiac marker with promise. Emerg. Med. J. 2006, 23, 875–877. [CrossRef] [PubMed]
8. Lund, J.; Qin, Q.-P.; Ilva, T.; Nikus, K.; Eskola, M.; Porela, P.; Kokkala, S.; Pulkki, K.; Pettersson, K.; Voipio-Pulkki, L.-M. Pregnancy-associated plasma protein A: A biomarker in acute ST-elevation myocardial infarction (STEMI). Ann. Med. 2006, 38, 221–228. [CrossRef]
9. Bonaca, M.P.; Scirica, B.M.; Sabatine, M.S.; Jarolim, P.; Murphy, S.A.; Chamberlin, J.S.; Rhodes, D.W.; Southwick, P.C.; Braunwald, E.; Morrow, D.A. Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 2012, 60, 332–338. [CrossRef]
10. Parveen, N.; Subbakumari, K.N.; Krishnan, S. Pregnancy associated plasma protein-a (PAPP-A) levels in acute coronary syndrome: A case control study in a tertiary care centre. Indian J. Clin. Biochem. 2015, 30, 150–154. [CrossRef]
11. Daidoji, H.; Takahashi, H.; Otaki, Y.; Tamura, H.; Arimoto, T.; Shishido, T.; Miyashita, T.; Miyamoto, T.; Watanabe, T.; Kubota, I. A combination of plaque components analyzed by integrated backscatter intravascular ultrasound and serum pregnancy-associated plasma protein a levels predict the no-reflow phenomenon during percutaneous coronary intervention. Catheter. Cardiovasc. Interv. 2015, 85, 43–50. [CrossRef] [PubMed]
12. Iversen, K.; Teisner, A.; Dalager, S.; Olsen, K.E.; Floridson, C.; Teisner, B. Pregnancy associated plasma protein-a (PAPP-A) is not a marker of the vulnerable atherosclerotic plaque. Clin. Biochem. 2011, 44, 312–318. [CrossRef] [PubMed]
13. Cosin-Sales, J.; Kaski, J.C.; Christiansen, M.; Kaminski, P.; Oxvig, C.; Overgaard, M.T.; Cole, D.; Holt, D.W. Relationship among pregnancy associated plasma protein-a levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur. Heart J. 2005, 26, 2093–2098. [CrossRef] [PubMed]
14. Consuegra-Sanchez, L.; Fredericks, S.; Kaski, J.C. Pregnancy-associated plasma protein-a (PAPP-A) and cardiovascular risk. Atherosclerosis 2009, 203, 346–352. [CrossRef] [PubMed]
15. Elesber, A.A.; Conover, C.A.; Denktas, A.E.; Lennon, R.J.; Holmes, D.R.J.; Overgaard, M.T.; Christiansen, M.; Oxvig, C.; Lerman, L.O.; Lerman, A. Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. *Eur. Heart J.* 2006, 27, 1678–1684. [CrossRef] [PubMed]

16. Consuegra-Sanchez, L.; Petrovic, I.; Cosin-Sales, J.; Holt, D.W.; Christiansen, M.; Kaski, J.C. Prognostic value of circulating pregnancy-associated plasma protein-a (PAPP-A) and proform of eosiunophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris. *Clin. Chim. Acta* 2008, 391, 18–23. [CrossRef]

17. Iversen, K.K.; Teisner, B.; Winkel, P.; Gluud, C.; Kjøller, E.; Kolmos, H.J.; Hildebrandt, P.R.; Hilden, J.; Kastrup, J. Pregnancy associated plasma protein-a as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the claricor trial. *Atherosclerosis* 2011, 214, 203–208. [CrossRef]

18. Schulz, O.; Reinicke, M.; Kramer, J.; Berghofer, G.; Bensch, R.; Schimke, I.; Jaffe, A. Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease: Use of a new monoclonal antibody-based assay. *Clin. Chim. Acta* 2011, 412, 880–886. [CrossRef]

19. Zengin, E.; Sinning, C.; Zeller, T.; Rupprecht, H.-J.; Schnabel, R.B.; Lackner, K.-J.; Blankenberg, S.; Westermann, D.; Bickel, C. The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease. *Biomark. Med.* 2015, 9, 731–741. [CrossRef]

20. Oxvig, C. The role of PAPP-A in the IGF system: Location, location, location. *J. Cell Commun. Signal.* 2015, 9, 177–187. [CrossRef]

21. Bayes-Genis, A.; Schwartz, R.S.; Lewis, D.A.; Overgaard, M.T.; Christiansen, M.; Oxvig, C.; Ashai, K.; Holmes, D.R.J.; Conover, C.A. Insulin-like growth factor binding protein-4 pro tease produced by smooth muscle cells increases in the coronary artery after angioplasty. *Arterioscler. Thromb. Vasc. Biol.* 2001, 21, 335–341. [CrossRef] [PubMed]

22. Conover, C.A. Key questions and answers about pregnancy-associated plasma protein-A. *Trends Endocrinol. Metab.* 2012, 23, 242–249. [CrossRef] [PubMed]

23. Winkel, P.; Jakobsen, J.C.; Hilden, J.; Lange, T.; Jensen, G.B.; Kjøller, E.; Sajadieh, A.; Kastrup, J.; Kolmos, H.J.; Larsson, A.; et al. Predictors for major cardiovascular outcomes in stable ischaemic heart disease (Preme car) Statistical analysis plan for data originating from the Claricor (clarithromycin for patients with stable coronary heart disease) trial. *Diagn. Progn. Res.* 2017, 1, 10. [CrossRef] [PubMed]

24. Jespersen, C.M.; Als-Nielsen, B.; Damgaard, M.; Hansen, J.F.; Hansen, S.; Hele, O.H.; Hildebrandt, P.; Hilden, J.; Jensen, G.B.; Kastrup, J.; et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: Claricor trial. *BMJ* 2006, 332, 22–27. [CrossRef]

25. Gluud, C.; Als-Nielsen, B.; Damgaard, M.; Fischer Hansen, J.; Hansen, S.; Hele, O.H.; Hildebrandt, P.; Hilden, J.; Jensen, G.B.; Kastrup, J.; et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. *Cardiology* 2008, 111, 280–287. [CrossRef]

26. Winkel, P.; Hilden, J.; Fischer Hansen, J.; Hildebrandt, P.; Kastrup, J.; Kolmos, H.J.; Kjøller, E.; Jespersen, C.M.; Gluud, C.; Jensen, G.B.; et al. Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: Why is this so, and why are statins protective? *Cardiology* 2011, 118, 63–67. [CrossRef]

27. Winkel, P.; Hilden, J.; Hansen, J.F.; Kastrup, J.; Kolmos, H.J.; Kjøller, E.; Jensen, G.B.; Skoog, M.; Lindschou, J.; Gluud, C.; et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. *Int. J. Cardiol.* 2015, 182, 459–465. [CrossRef]

28. Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F.; Feldman, H.I.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Greene, T.; et al. A new equation to estimate glomerular filtration rate. *Ann. Intern. Med.* 2009, 150, 604–612. [CrossRef]

29. Rossen, M.; Iversen, K.; Teisner, A.; Teisner, B.; Kliem, A.; Grudzinskas, G. Optimisation of sandwich ELISA based on monoclonal antibodies for the specific measurement of pregnancy-associated plasma protein (PAPP-A) in acute coronary syndrome. *Clin. Biochem.* 2007, 40, 478–484. [CrossRef]

30. Kjøller, E.; Hilden, J.; Winkel, P.; Galatius, S.; Frandsen, N.J.; Jensen, G.B.; Fischer Hansen, J.; Kastrup, J.; Jespersen, C.M.; Hildebrandt, P.; et al. Agreement between public register and adjudication committee outcome in a cardiovascular randomized controlled clinical trial. *Am. Heart J.* 2014, 168, 197–204. [CrossRef]
31. Kjoller, E.; Hilden, J.; Winkel, P.; Frandsen, N.J.; Galatius, S.; Jensen, G.; Kastrup, J.; Hansen, J.F.; Kolmos, H.J.; Jespersen, C.M.; et al. Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease. *J. Clin. Epidemiol.* **2012**, *65*, 444–453. [CrossRef] [PubMed]

32. Pellitero, S.; Reverter, J.L.; Granada, M.L.; Pizarro, E.; Pastor, M.C.; Tassies, D.; Reverter, J.C.; Salinas, I.; Sanmarti, A. Association of the IGF1/pregnancy-associated plasma protein-a system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control. *Eur. J. Endocrinol.* **2009**, *160*, 925–932. [CrossRef] [PubMed]

33. Schisterman, E.F.; Cole, S.R.; Platt, R.W. Overadjustment bias and unnecessary adjustment in epidemiologic studies. *Epidemiology* **2009**, *20*, 488–495. [CrossRef] [PubMed]

34. Resch, Z.T.; Simari, R.D.; Conover, C.A. Targeted disruption of the pregnancy-associated plasma protein-a gene is associated with diminished smooth muscle cell response to insulin-like growth factor-i and resistance to neointimal hyperplasia after vascular injury. *Endocrinology* **2006**, *147*, 5634–5640. [CrossRef]

35. Conover, C.A.; Mason, M.A.; Bale, L.K.; Harrington, S.C.; Nyegaard, M.; Oxvig, C.; Overgaard, M.T. Transgenic overexpression of pregnancy-associated plasma protein-a in murine arterial smooth muscle accelerates atherosclerotic lesion development. *Am. J. Physiol. Heart Circ. Physiol.* **2010**, *299*, H284–H291. [CrossRef]

36. Conover, C.A.; Bale, L.K.; Oxvig, C. Targeted inhibition of pregnancy-associated plasma protein-a activity reduces atherosclerotic plaque burden in mice. *J. Cardiovasc. Trans. Res.* **2016**, *9*, 77–79. [CrossRef]

37. Swindell, W.R.; Masternak, M.M.; Bartke, A. In vivo analysis of gene expression in long-lived mice lacking the pregnancy-associated plasma protein A (PappA) gene. *Exp. Gerontol.* **2010**, *45*, 366–374. [CrossRef]

38. Root, A. Growth hormone. *Pediatrics* **1965**, *36*, 940–950.

39. Palmeiro, C.R.; Anand, R.; Dardi, I.K.; Balasubramaniyam, N.; Schwarz, M.D.; Weiss, I.A. Growth hormone and the cardiovascular system. *Cardiol. Rev.* **2012**, *20*, 197–207. [CrossRef]

40. Hjortebjerg, R. IGFBP-4 and PAPP-A in normal physiology and disease. *Growth Horm. IGF Res.* **2018**, *41*, 7–22. [CrossRef]

41. Guo, Y.; Bao, Y.; Guo, D.; Yang, W. Pregnancy-associated plasma protein a in cancer: Expression, oncogenic functions and regulation. *Am. J. Cancer. Res.* **2018**, *8*, 955–963. [PubMed]

42. Bale, L.K.; Resch, Z.T.; Harstad, S.L.; Overgaard, M.T.; Conover, C.A. Constitutive expression of pregnancy-associated plasma protein-a in arterial smooth muscle reduces the vascular response to injury in vivo. *Am. J. Physiol. Endocrinol. Metab.* **2013**, *304*, E139–E144. [CrossRef] [PubMed]

43. Mosholder, A.D.; Lee, J.Y.; Zhou, E.H.; Kang, E.M.; Ghosh, M.; Izem, R.; Major, J.M.; Graham, D.J. Long-term risk of acute myocardial infarction, stroke, and death with outpatient use of clarithromycin: A retrospective cohort study. *Am. J. Epidemiol.* **2018**, *187*, 786–792. [CrossRef] [PubMed]

44. Solomon, S.D.; Claggett, B.; Desai, A.S.; Packer, M.; Zile, M.; Swedberg, K.; Rouleau, J.L.; Shi, V.C.; Starling, R.C.; Kozan, Ö.; et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: The prospective comparison of arni with acei to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. *Circ. Heart Fail.* **2016**, *9*, e002744. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).